Hodgkin lymphoma: Response assessment by revised international workshop criteria

被引:50
作者
Brepoels, Lieselot
Stroobants, Sigrid
De Wever, Walter
Spaepen, Karoline
Vandenberghe, Peter
Thomas, Jose
Uyttebroeck, Anne
Mortelmans, Luc
De Wolf-Peeters, Christiane
Verhoef, Gregor
机构
[1] Univ Hosp Gasthuisberg, Dept Nucl Med, B-3000 Louvain, Belgium
[2] Univ Hosp Gasthuisberg, Dept Radiol, B-3000 Louvain, Belgium
[3] Univ Hosp Gasthuisberg, Ctr Human Genet, B-3000 Louvain, Belgium
[4] Univ Hosp Gasthuisberg, Dept Clin Oncol, B-3000 Louvain, Belgium
[5] Univ Hosp Gasthuisberg, Dept Pediat Hemato Oncol, B-3000 Louvain, Belgium
[6] Univ Hosp Gasthuisberg, Dept Pathol, B-3000 Louvain, Belgium
[7] Univ Hosp Gasthuisberg, Dept Hematol, B-3000 Louvain, Belgium
[8] Catholic Univ Louvain, B-3000 Louvain, Belgium
关键词
Hodgkin's lymphoma; response assessment; CT; PET;
D O I
10.1080/10428190701422414
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Until recently, response assessment in patients with Hodgkin's lymphoma (HL) was primarily performed by computed tomography (CT). Based on CT, International Workshop Criteria (IWC) were developed and widely used. Fluorodeoxyglucose positron emission tomography (FDG-PET) has a higher sensitivity and specificity compared with that of CT, and Revised International Workshop Criteria (IWC+PET) were recently proposed, which combine both imaging techniques. We determined whether these integrated IWC+PET-criteria can more accurately predict outcome compared with IWC-criteria in 56 patients with HL. Of the original 56 patients, nine patients relapsed and 47 are still in remission after a median follow-up of 9 years. Based on IWC-criteria, 15 patients had a complete remission (CR) after chemotherapy, 20 had complete remission unconfirmed (CRu), 19 had partial remission (PR) and two had stable disease (SD). In comparison, by IWC+PET, 47 had CR, seven had PR and two had SD. For IWC, outcome was not significantly different in patients with CR/ CRu compared to PR (P = 0.61), while for IWC+PET criteria, time-to-next-treatment was significantly shorter in patients with PR compared to CR (P = 0.01). Therefore, IWC+PET-guidelines provide a more accurate response classification compared with that of IWC-guidelines, and are the preferred method for response assessment in patients with Hodgkin's lymphoma.
引用
收藏
页码:1539 / 1547
页数:9
相关论文
共 26 条
[1]   Staging non-Hodgkin lymphoma [J].
Armitage, JO .
CA-A CANCER JOURNAL FOR CLINICIANS, 2005, 55 (06) :368-376
[2]   Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].
Cheson, BD ;
Horning, SJ ;
Coiffier, B ;
Shipp, MA ;
Fisher, RI ;
Connors, JM ;
Lister, TA ;
Vose, J ;
Grillo-López, A ;
Hagenbeek, A ;
Cabanillas, F ;
Klippensten, D ;
Hiddemann, W ;
Castellino, R ;
Harris, NL ;
Armitage, JO ;
Carter, W ;
Hoppe, R ;
Canellos, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253
[3]   Revised response criteria for malignant lymphoma [J].
Cheson, Bruce D. ;
Pfistner, Beate ;
Juweid, Malik E. ;
Gascoyne, Randy D. ;
Specht, Lena ;
Horning, Sandra J. ;
Coiffier, Bertrand ;
Fisher, Richard I. ;
Hagenbeek, Anton ;
Zucca, Emanuele ;
Rosen, Steven T. ;
Stroobants, Sigrid ;
Lister, T. Andrew ;
Hoppe, Richard T. ;
Dreyling, Martin ;
Tobinai, Kensei ;
Vose, Julie M. ;
Connors, Joseph M. ;
Federico, Massimo ;
Diehl, Volker .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586
[4]   18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma [J].
de Wit, M ;
Bohuslavizki, KH ;
Buchert, R ;
Bumann, D ;
Clausen, M ;
Hossfeld, DK .
ANNALS OF ONCOLOGY, 2001, 12 (01) :29-37
[5]  
Eghbali H, 2005, BLOOD, V106, p240A
[6]   FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo hodgkin lymphoma:: A blinded comparison [J].
Friedberg, JW ;
Fischman, A ;
Neuberg, D ;
Kim, H ;
Takvorian, T ;
Ng, AK ;
Mauch, PM ;
Canellos, GP ;
Van den Abbeele, AD .
LEUKEMIA & LYMPHOMA, 2004, 45 (01) :85-92
[7]   MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: The 8-year results of the Intergroup trial [J].
Glick, JH ;
Young, ML ;
Harrington, D ;
Schilsky, RL ;
Beck, T ;
Neiman, R ;
Fisher, RI ;
Peterson, BA ;
Oken, MM .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :19-26
[8]  
Guay C, 2003, J NUCL MED, V44, P1225
[9]   Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group Pilot Study E1492 [J].
Horning, SJ ;
Wiliams, J ;
Bartlett, NL ;
Bennett, JM ;
Hoppe, RT ;
Neuberg, D ;
Cassileth, P .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (05) :972-980
[10]  
Hueltenschmidt B, 2001, CANCER-AM CANCER SOC, V91, P302, DOI 10.1002/1097-0142(20010115)91:2<302::AID-CNCR1002>3.0.CO